GCP, a genistein-rich compound, inhibits proliferation and induces apoptosis in lymphoma cell lines

Leukemia Research

Volumn 34, Issue 1, 2010, Pages 69-76

  McCall, Jamie L ^a   Burich, Rebekah A ^a   Mack, Philip C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

GCP; Genistein combined polysaccharide; Lymphoma

Indexed keywords

GENISTEIN; GENISTEIN COMBINED POLYSACCHARIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DOG; DRUG EFFICACY; DRUG SCREENING; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOMA; LYMPHOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA DAMAGE; DOGS; FLOW CYTOMETRY; GENISTEIN; HUMANS; IN SITU NICK-END LABELING; LYMPHOMA; POLYSACCHARIDES;

EID: 73249121083     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.03.025     Document Type: Article

References (43)

1. Cancer Facts and Figures 2008. Atlanta: American Cancer Society; 2008.
2. Pryzant R.M., Meistrich M.L., Wilson G., Brown B., and McLaughlin P. Long-term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin's lymphomas. J Clin Oncol 11 (1993) 239-247
3. Chen G.L., Yang L., Rowe T.C., Halligan B.D., Tewey K.M., and Liu L.F. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259 (1984) 13560-13566
4. Armitage J.O., and Potter J.F. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc 32 (1984) 269-273
5. Dixon D.O., Neilan B., Jones S.E., Lipschitz D.A., Miller T.P., Grozea P.N., et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 4 (1986) 295-305
6. Ferlay J., Bray F., Pisani P., and Parkin D.M. GLOBOCAN 2002. Cancer incidence, mortality, and prevalence worldwide (2004), IARC Press, Lyon, France
7. Sarkar F.H., and Li Y. Soy isoflavones and cancer prevention. Cancer Invest 21 (2003) 744-757
8. Mills P.K., Beeson W.L., Phillips R.L., and Fraser G.E. Cohort study of diet, lifestyle, and prostate cancer in adventist men. Cancer 64 (1989) 598-604
9. Muir C.S., Nectoux J., and Staszewski J. The epidemiology of prostatic cancer. Geographical distribution and time-trends. Acta Oncol 30 (1991) 133-140
10. Shimizu H., Ross R.K., Bernstein L., Yatani R., Henderson B.E., and Mack T.M. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 63 (1991) 963-966
11. Atkinson C., Frankenfeld C.L., and Lampe J.W. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med (Maywood) 230 (2005) 155-170
12. Setchell K.D., Brown N.M., Desai P., Zimmer-Nechemias L., Wolfe B.E., Brashear W.T., et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 131 (2001) 1362S-1375S
13. Szkudelska K., and Nogowski L. Genistein-A dietary compound inducing hormonal and metabolic changes. J Steroid Biochem Mol Biol (2007)
14. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., et al. Genistein a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262 (1987) 5592-5595
15. Li Y., and Sarkar F.H. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 8 (2002) 2369-2377
16. Park S.S., Kim Y.N., Jeon Y.K., Kim Y.A., Kim J.E., Kim H., et al. Genistein-induced apoptosis via Akt signaling pathway in anaplastic large-cell lymphoma. Cancer Chemother Pharmacol 56 (2005) 271-278
17. Sarkar F.H., and Li Y. Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev 21 (2002) 265-280
18. Baxa D.M., Luo X., and Yoshimura F.K. Genistein induces apoptosis in T lymphoma cells via mitochondrial damage. Nutr Cancer 51 (2005) 93-101
19. Alhasan S.A., Pietrasczkiwicz H., Alonso M.D., Ensley J., and Sarkar F.H. Genistein-induced cell cycle arrest and apoptosis in a head and neck squamous cell carcinoma cell line. Nutr Cancer 34 (1999) 12-19
20. Lian F., Bhuiyan M., Li Y.W., Wall N., Kraut M., and Sarkar F.H. Genistein-induced G2-M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr Cancer 31 (1998) 184-191
21. Spinozzi F., Pagliacci M.C., Migliorati G., Moraca R., Grignani F., Riccardi C., et al. The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leuk Res 18 (1994) 431-439
22. Setchell K.D., Brown N.M., Zimmer-Nechemias L., Brashear W.T., Wolfe B.E., Kirschner A.S., et al. Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. Am J Clin Nutr 76 (2002) 447-453
23. Miura T., Yuan L., Sun B., Fujii H., Yoshida M., Wakame K., et al. Isoflavone aglycon produced by culture of soybean extracts with basidiomycetes and its anti-angiogenic activity. Biosci Biotechnol Biochem 66 (2002) 2626-2631
24. deVere White R.W., Hackman R.M., Soares S.E., Beckett L.A., Li Y., and Sun B. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology 63 (2004) 259-263
25. deVere White R.W., Hackman R.M., Soares S.E., Beckett L.A., and Sun B. Effects of a mushroom mycelium extract on the treatment of prostate cancer. Urology 60 (2002) 640-644
26. Akaza H., Miyanaga N., Takashima N., Naito S., Hirao Y., Tsukamoto T., et al. Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration. Jpn J Clin Oncol 32 (2002) 296-300
27. Ghafar M.A., Golliday E., Bingham J., Mansukhani M.M., Anastasiadis A.G., and Katz A.E. Regression of prostate cancer following administration of genistein combined polysaccharide (GCP), a nutritional supplement: a case report. J Altern Complement Med 8 (2002) 493-497
28. Tepper C.G., Vinall R.L., Wee C.B., Xue L., Shi X.-B., Burich R., et al. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms. Prostate 67 (2007) 521-535
29. Bemis D.L., Capodice J.L., Desai M., Buttyan R., and Katz A.E. A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo. Clin Cancer Res 10 (2004) 5282-5292
30. Burich R.A., Holland W.S., Vinall R.L., Tepper C., Devere White R.W., and Mack P.C. Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines. BJU Int (2008)
31. Kaufmann S.H., Desnoyers S., Ottaviano Y., Davidson N.E., and Poirier G.G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 53 (1993) 3976-3985
32. Dobson J.M., Blackwood L.B., Mcinnes E.F., Bostock D.E., Nicholls P., Hoather T.M., et al. Prognostic variables in canine multicentric lymphosarcoma. J Small Anim Prac 42 (2001) 377-384
33. Sevilla D.W., Gong J.Z., Goodman B.K., Buckley P.J., Rosoff P., Gockerman J.P., et al. Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation. Am J Clin Pathol 128 (2007) 981-991
34. Diffuse small noncleaved-cell/Burkitt lymphoma. [Internet]: National Cancer Institute, U.S. National Institutes of Health; 2008 06/06/2008 - [cited September 19, 2008] Available from: http://www.cancer.gov/cancertopics/pdq/treatment/adult-non-hodgkins/HealthProfessional/page12.
35. Shaposhnikov S.A., Salenko V.B., Brunborg G., Nygren J., and Collins A.R. Single-cell gel electrophoresis (the comet assay): loops or fragments?. Electrophoresis 29 (2008) 3005-3012
36. Anderson D., Dobrzynska M.M., and Basaran N. Effect of various genotoxins and reproductive toxins in human lymphocytes and sperm in the Comet assay. Teratog Carcinog Mutagen 17 (1997) 29-43
37. Foti P., Erba D., Riso P., Spadafranca A., Criscuoli F., and Testolin G. Comparison between daidzein and genistein antioxidant activity in primary and cancer lymphocytes. Arch Biochem Biophys 433 (2005) 421-427
38. Morley N., Rapp A., Dittmar H., Salter L., Gould D., Greulich K.O., et al. UVA-induced apoptosis studied by the new apo/necro-Comet-assay which distinguishes viable, apoptotic and necrotic cells. Mutagenesis 21 (2006) 105-114
39. Markovits J., Linassier C., Fosse P., Couprie J., Pierre J., Jacquemin-Sablon A., et al. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res 49 (1989) 5111-5117
40. Wilstermann A.M., and Osheroff N. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr Top Med Chem 3 (2003) 321-338
41. Lock R.B., and Ross W.E. Inhibition of p34cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in Chinese hamster ovary cells. Cancer Res 50 (1990) 3761-3766
42. Fournel-Fleury C., Magnol J.P., Bricaire P., Marchal T., Chabanne L., Delverdier A., et al. Cytohistological and immunological classification of canine malignant lymphomas: comparison with human non-Hodgkin's lymphomas. J Comp Pathol 117 (1997) 35-59
43. Ponce F., Magnol J.-P., Ledieu D., Marchal T., Turinelli V., Chalvet-Monfray K., et al. Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. Vet J 167 (2004) 158-166